OPEN ACCESS Freely available online

Review Article

Vol. 1, Issue 2, July-December 2026 | ISSN: 3139-6267

Journal of Artificial Intelligence and Digital Health

A Conceptual Framework for AI-Integrated Metabolomics in Predictive Health Systems for Resource-Constrained Environments

David Sunday Araoti*

Department of Research, Policy and AI Governance, Independent Researcher, Ogbomosho, Nigeria

***Correspondence to:** David Sunday Araoti, Department of Research, Policy and AI Governance, Independent Researcher, Ogbomosho, Nigeria, E-mail: davidaraoti@gmail.com

Received: May 22, 2026; **Manuscript No:** JAID-26-9980; **Editor Assigned:** May 26, 2026; **PreQc No:** JAID-26-9980 (PQ); **Reviewed:** June 05, 2025; **Revised:** July 21, 2026; **Manuscript No:** JAID-26-9980 (R); **Published:** August 03, 2026

Citation: Araoti DS (2026). A Conceptual Framework for AI-Integrated Metabolomics in Predictive Health Systems for Resource-Constrained Environments. J. Artif. Intell. Digit. Health. Vol.1 Iss.2, August (2026), pp:124-130.

ABSTRACT

The increasing prevalence of non-communicable diseases (NCDs) continues to place significant pressure on healthcare systems, particularly in low- and middle-income regions where access to early diagnostic infrastructure remains limited. Conventional healthcare approaches are often reactive, detecting diseases after substantial progression and reducing opportunities for timely intervention. This challenge highlights the need for predictive, affordable, and data-driven healthcare solutions that can support early diagnosis and prevention.

This study proposes a conceptual framework that integrates metabolomics with artificial intelligence (AI) to support predictive health systems in resource-constrained environments. Metabolomics enables comprehensive characterization of small-molecule metabolites, providing valuable insights into physiological and pathological changes. When combined with machine learning approaches, metabolomic datasets can be analyzed to identify potential biomarkers, classify disease risks, and generate personalized healthcare insights.

The proposed framework presents a multi-layered architecture consisting of metabolomic data acquisition, preprocessing, feature engineering, AI-based predictive modeling, and clinical decision-support outputs. The model emphasizes scalability through the integration of portable diagnostic technologies, cloud-based analytics, edge computing, and decentralized healthcare delivery approaches. It also considers critical implementation challenges, including data harmonization, infrastructure limitations, algorithmic bias, and ethical governance.

Furthermore, the framework highlights the need for empirical validation through pilot studies, technology assessment, and multi-site evaluation to determine its feasibility, reliability, and applicability across diverse healthcare settings. By integrating biological data analysis, computational intelligence, and responsible innovation principles, this study provides a pathway toward accessible predictive and precision public health systems for underserved populations.

Overall, this research contributes to the advancement of AI-enabled healthcare by proposing a scalable and context-sensitive model that bridges metabolomics, artificial intelligence, and healthcare delivery requirements in resource-constrained environments.

Keywords: Metabolomics; Artificial Intelligence; Predictive Healthcare; Biomarkers; Precision Medicine; Digital Health; Resource-Constrained Environments

INTRODUCTION

The global health burden associated with non-communicable diseases (NCDs) has increased substantially over the past decades, posing a major challenge to healthcare systems worldwide. Conditions such as cardiovascular diseases, diabetes, and cancer account for a significant proportion of morbidity and mortality, with low- and middle-income countries experiencing the greatest impact due to limited access to early diagnostic and preventive services [1]. Unlike acute infectious diseases, NCDs typically develop gradually and often remain undetected during their early stages, thereby reducing opportunities for timely intervention and increasing long-term healthcare costs.

In response to these challenges, there has been a growing shift from reactive healthcare models toward predictive and preventive approaches. This transition is largely driven by advancements in biomedical research and digital health technologies. One such advancement is metabolomics, a field focused on the large-scale analysis of small-molecule metabolites present within biological systems. Because metabolites reflect ongoing biochemical activities, metabolomic profiling provides a dynamic representation of physiological states and can reveal early alterations associated with disease onset [2-3]. This capability makes metabolomics particularly valuable for early detection, biomarker discovery, and disease monitoring.

At the same time, artificial intelligence (AI) has emerged as a transformative tool in healthcare, enabling the analysis of complex and high-dimensional datasets. Machine learning techniques, a core subset of AI, are especially effective in identifying patterns, correlations, and predictive signals that may not be detectable using conventional statistical approaches. These methods have been successfully applied in areas such as diagnostics, risk prediction, and personalized treatment planning [4-5]. When applied to metabolomic data, AI-driven models can enhance the identification of disease-related metabolic signatures and improve predictive accuracy.

The integration of metabolomics and AI therefore represents a promising direction for the development of predictive health systems. By combining biologically rich data with advanced computational techniques, it becomes possible to detect disease risks at earlier stages, support clinical decision-making, and tailor interventions to individual patient profiles. This interdisciplinary approach aligns with the broader concept of precision medicine, which seeks to optimize healthcare delivery through data-driven insights and individualized treatment strategies.

Despite its potential, the application of AI-integrated metabolomics remains limited in resource-constrained environments. Several barriers hinder adoption, including the high cost of analytical technologies, limited laboratory infrastructure, inadequate data management systems, and a shortage of technical expertise. In addition, challenges related to data privacy, ethical governance, and regulatory frameworks further complicate implementation efforts [6]. These constraints highlight the need for innovative and adaptable solutions that can bridge the gap between advanced scientific capabilities and real-world healthcare needs in underserved regions.

This study addresses this gap by proposing a conceptual framework for integrating metabolomics and artificial intelligence into predictive health systems tailored for low-resource settings. The framework emphasizes scalability, cost-efficiency, and accessibility, incorporating emerging technologies such as portable diagnostic tools and cloud-based data platforms. By aligning technological innovation with local healthcare contexts, the proposed model aims to improve early disease detection, enhance clinical decision-making, and reduce the burden of non-communicable diseases.

Furthermore, this research contributes to the evolving field of precision public health, which focuses on applying data-driven approaches to improve population health outcomes. By bridging biological science and computational intelligence within a practical healthcare framework, the study provides a pathway for translating advanced research into actionable solutions for resource-limited environments. Ultimately, it underscores the importance of interdisciplinary collaboration, policy support, and ethical responsibility in shaping the future of global health systems.

LITERATURE REVIEW

The intersection of metabolomics and artificial intelligence (AI) has become an increasingly important area of research in the pursuit of improved disease prediction and personalized healthcare. Existing studies across these domains highlight substantial progress; however, critical gaps remain, particularly regarding implementation in resource-constrained environments.

Metabolomics has gained recognition as a powerful tool for investigating biochemical processes and identifying disease-associated biomarkers. By analyzing metabolite profiles in biological samples such as blood, urine, and tissue extracts, researchers can detect subtle physiological alterations that precede clinical symptoms. Early foundational work demonstrated that metabolomic signatures can reflect systemic responses to pathological conditions and environmental influences [7-8]. More recent studies have extended these findings, showing that metabolomics can support early detection of complex diseases, including cancer, metabolic disorders, and neurodegenerative conditions [3,9].

Despite these advances, limitations persist in the clinical translation of metabolomics. One major challenge is the variability of metabolite profiles across populations due to differences in genetics, diet, environment, and lifestyle. This variability complicates the identification of universal biomarkers and reduces the generalizability of findings. In addition, the lack of standardized protocols for data acquisition and analysis continues to affect reproducibility across studies [10]. These issues suggest that while metabolomics holds strong diagnostic potential, its application requires context-specific calibration and methodological consistency.

Parallel to developments in metabolomics, artificial intelligence has transformed data analysis within healthcare systems. Machine learning algorithms, including supervised and unsupervised models, have demonstrated the ability to process large-scale biomedical datasets and extract meaningful patterns. Applications range from image-based diagnostics to predictive analytics and clinical decision support [4]. Deep learning techniques, in particular, have achieved high levels of accuracy in classification and pattern recognition tasks, often surpassing traditional analytical methods [5]. These capabilities position AI as a critical enabler of data-driven healthcare innovation.

However, the effectiveness of AI in healthcare is highly dependent on data quality, availability, and representativeness. Many models are trained on datasets derived from high-resource settings, which may not reflect the demographic and environmental diversity of low- and middle-income regions. This raises concerns about algorithmic bias and limits the applicability of such models in underserved populations [6]. Furthermore, the reliance on large, well-curated datasets presents a significant barrier in contexts where data infrastructure is weak or fragmented.

The integration of metabolomics and AI has emerged as a promising strategy to enhance predictive healthcare capabilities. Studies have shown that combining metabolomic data with machine learning techniques can improve the identification of disease-specific biomarkers and enable more accurate risk prediction [11,12]. This interdisciplinary approach leverages the strengths of both fields: the biological sensitivity of metabolomics and the analytical power of AI. As a result, it supports the development of predictive models that are both biologically informed and computationally robust.

Nevertheless, existing research in this integrated domain remains largely focused on high-resource environments, with limited attention to practical implementation in low-resource settings. Key challenges include the high cost of metabolomic technologies such as mass spectrometry and nuclear magnetic resonance systems, as well as the need for specialized technical expertise. Although emerging portable diagnostic tools and cloud-based analytics offer potential solutions, their scalability and reliability require further validation [13].

Another critical gap in the literature relates to the lack of holistic frameworks that address both technological and contextual factors. While many studies emphasize technical feasibility, fewer consider the broader ecosystem required for successful deployment, including infrastructure, policy support, workforce capacity, and ethical governance. Issues such as data privacy, informed consent, and equitable access are particularly important in regions where regulatory systems may be underdeveloped.

In summary, the existing body of literature demonstrates the significant potential of metabolomics and AI in advancing predictive healthcare. However, there remains a clear need for integrative, context-sensitive approaches that address both scientific and practical challenges. This study builds upon prior research by proposing a conceptual framework that not only integrates metabolomics and AI but also considers the unique constraints and opportunities present in resource-limited environments. By doing so, it aims to bridge the gap between technological innovation and real-world healthcare application [14].

METHODOLOGY

This study adopts a conceptual and integrative research design aimed at developing a structured framework for the application of artificial intelligence (AI)-integrated metabolomics in predictive health systems within resource-constrained environments. Rather than conducting primary experimental or clinical investigations, the methodology synthesizes existing scientific knowledge, computational principles, and healthcare system dynamics to construct a scalable and context-sensitive model. The approach is grounded in systems thinking, recognizing healthcare delivery as an interconnected ecosystem involving biological data, analytical technologies, institutional structures, and socio-economic conditions.

Conceptual Framework Design

The foundation of the methodology lies in the development of a multi-layered system architecture that integrates metabolomic data processing with AI-driven predictive analytics. The framework is designed to simulate the end-to-end workflow of a predictive health system, from biological data acquisition to clinical decision support. It consists of five interrelated layers:

- Data Acquisition
- Data Preprocessing
- Feature Engineering
- Ai-Based Modeling
- Decision-Support Output

Data Acquisition Layer

At the input level, the framework conceptualizes the collection of metabolomic data from biological samples such as blood, urine, or saliva. These samples contain small-molecule metabolites that reflect ongoing biochemical processes within the body. In resource-constrained environments, the model emphasizes the use of portable and cost-effective diagnostic tools capable of generating metabolite profiles with reasonable accuracy [15-16]. This layer is designed to accommodate both centralized laboratory systems and decentralized point-of-care data collection.

Data Preprocessing and Transformation

Following data acquisition, raw metabolomic data undergoes preprocessing to ensure quality, consistency, and usability. This stage includes normalization to correct for variations in sample concentration, noise reduction to eliminate irrelevant signals, and missing-value handling to improve dataset completeness. Given the high dimensionality of metabolomic data, dimensionality reduction techniques are conceptually incorporated to enhance computational efficiency. Methods such as principal component analysis (PCA) and feature scaling are considered essential for transforming raw data into structured analytical inputs.

Feature Engineering and Selection

The next stage involves identifying and extracting biologically relevant features from the processed dataset. Feature engineering focuses on isolating metabolic signatures that are strongly associated with specific disease conditions. This may involve statistical correlation analysis, clustering techniques, or domain-informed selection of biomarkers. The objective is to reduce data complexity while preserving critical information necessary for accurate prediction. In resource-limited contexts, this step is particularly important for optimizing computational efficiency and minimizing processing costs.

AI-Based Predictive Modeling

The core analytical component of the framework is the integration of machine learning models for predictive analysis. Supervised learning algorithms, such as Random Forest, Support Vector Machines (SVM), and logistic regression, are conceptually applied to classify disease risk and predict potential health outcomes. In addition, neural network architectures may be utilized to capture complex, non-linear relationships within metabolomic data. These models are trained to recognize patterns associated with disease onset, progression, and metabolic abnormalities.

To ensure interpretability, the framework emphasizes the use of explainable AI techniques, enabling healthcare practitioners to understand the rationale behind model predictions. This is particularly important in clinical environments where transparency and trust are essential for adoption.

Decision-Support and Clinical Output

The outputs generated by the AI models are translated into clinically meaningful insights within the decision-support layer.

These outputs may include risk scores, probability estimates, and diagnostic alerts that assist healthcare providers in making informed decisions [17-18]. The framework is designed to present results in a simplified and actionable format, ensuring usability even in settings with limited specialist expertise. This layer bridges the gap between computational analysis and real-world healthcare delivery.

Adaptation to Resource-Constrained Environments

A key feature of the proposed methodology is its adaptability to low-resource settings. The framework incorporates a hybrid architecture that combines edge computing and cloud-based analytics. Data may be collected locally using portable devices and processed either on-site (edge) or remotely via cloud platforms, depending on infrastructure availability. This flexibility ensures that the system remains functional in environments with intermittent internet connectivity and limited computational resources [18].

Ethical and Data Governance Considerations

Ethical considerations are integrated throughout the methodological design. The framework emphasizes data privacy, secure storage, and responsible data sharing practices. Informed consent and transparency in data usage are considered essential principles. Additionally, the methodology acknowledges the risk of algorithmic bias and proposes the use of diverse and representative datasets to improve model fairness and generalizability. Continuous monitoring and validation are recommended to ensure ethical compliance.

Iterative Learning and System Improvement

Finally, the framework incorporates an adaptive feedback mechanism that allows continuous system refinement. As new metabolomic and clinical data become available, the predictive models can be updated and retrained to improve accuracy over time. This iterative learning process ensures that the system evolves in response to changing healthcare needs and environmental conditions.

RESULTS AND DISCUSSION

This section presents a conceptual evaluation of the proposed AI-integrated metabolomics framework and discusses its potential implications for predictive healthcare delivery in resource-constrained environments. Given the non-empirical nature of this study, the results are derived from logical synthesis of existing scientific evidence and the functional relationships embedded within the proposed system architecture.

Conceptual Outcomes of the Framework

One of the primary outcomes of the proposed framework is the enhanced capability for early disease detection through metabolite-based analysis. Metabolites serve as sensitive indicators of biochemical activity and reflect real-time physiological changes within the body. By applying machine learning algorithms to metabolomic datasets, the framework enables the identification of subtle metabolic variations that may signal the early onset of disease. This approach offers a significant advantage over conventional diagnostic systems, which often rely on symptomatic presentation and may fail to detect diseases at an early stage.

In addition to early detection, the framework supports predictive risk stratification. The integration of AI models allows for the classification of individuals into varying risk categories based on their metabolic profiles. This stratification facilitates targeted intervention strategies, enabling healthcare providers to allocate resources more efficiently and prioritize high-risk populations. In resource-limited settings, where healthcare capacity is often constrained, such prioritization can contribute to improved system efficiency and patient outcomes.

Another key outcome is the improvement of clinical decision support. The framework translates complex metabolomic data into simplified, interpretable outputs such as risk scores, probability estimates, and diagnostic alerts. These outputs can assist healthcare practitioners in making informed decisions, particularly in environments where access to specialized expertise is limited. The inclusion of explainable AI principles further enhances trust and usability by providing transparency in how predictions are generated.

Implications for Healthcare Systems in Resource-Constrained Environments

The proposed framework demonstrates strong potential for improving healthcare delivery in low-resource settings through its emphasis on scalability and adaptability. By incorporating portable diagnostic technologies and decentralized data collection methods, the system reduces reliance on centralized laboratory infrastructure. This enables broader access to diagnostic services, particularly in rural or underserved regions.

The use of cloud-based computing further enhances scalability by allowing large-scale data processing without the need for extensive local computational resources. At the same time, the integration of edge computing ensures that basic analytical functions can be performed locally in environments with limited or intermittent internet connectivity. This hybrid approach supports flexible deployment across diverse healthcare contexts.

From a public health perspective, the framework contributes to a shift from reactive to preventive care models. By enabling early detection and risk prediction, the system supports proactive intervention strategies that can reduce disease burden and associated healthcare costs over time. This aligns with global efforts to strengthen health systems through data-driven and preventive approaches.

Limitations and Practical Constraints

Despite its potential, the framework is subject to several limitations that must be considered. One significant challenge is the inherent variability in metabolomic data. Metabolic profiles are influenced by a wide range of factors, including genetics, diet, environmental exposure, and lifestyle. This variability can introduce noise into predictive models and affect their generalizability across different populations. As a result, localized data calibration and population-specific model training are essential for improving accuracy.

Another limitation relates to infrastructure and technology access. High-quality metabolomic analysis traditionally requires advanced instruments such as mass spectrometry and nuclear magnetic resonance systems, which may be cost-prohibitive in low-resource settings. While portable diagnostic tools offer a promising alternative, their performance and standardization require further validation before widespread adoption.

Data-related challenges also pose significant constraints. AI models depend on large, high-quality datasets for effective training and validation. In many developing regions, data collection systems are fragmented, and issues such as incomplete records and inconsistent data formats can hinder model performance. Strengthening data infrastructure is therefore a critical requirement for successful implementation.

Ethical and Governance Considerations

The deployment of AI-integrated metabolomics systems raises important ethical and governance concerns. The handling of sensitive biological data necessitates robust data protection measures to ensure privacy and security. Informed consent and transparency in data usage are essential to maintain public trust.

Algorithmic bias represents another critical concern. If training datasets do not adequately reflect diverse populations, predictive models may produce unequal outcomes across demographic groups. Addressing this issue requires the use of inclusive datasets, continuous model evaluation, and the implementation of fairness-aware algorithms.

In addition, regulatory frameworks must be established to guide the responsible use of AI in healthcare. This includes defining standards for data governance, system validation, and accountability in decision-making processes. Without such frameworks, the adoption of advanced digital health technologies may face significant resistance.

Policy and Implementation Implications

For the proposed framework to be effectively implemented, coordinated efforts are required at multiple levels. Governments and healthcare institutions must invest in digital infrastructure, including data management systems and cloud-based platforms. Capacity building in areas such as bioinformatics, data science, and computational biology is also essential to support system operation and maintenance.

Furthermore, collaboration between researchers, policymakers, and technology developers is necessary to ensure that solutions are aligned with local healthcare needs. International partnerships may also play a role in facilitating knowledge transfer and resource sharing, particularly in low- and middle-income countries.

Future Validation and Implementation Roadmap

Empirical Validation of the Proposed Framework

Although this study presents a conceptual framework, future research should validate its effectiveness through pilot implementation studies in real healthcare environments. Validation should involve deploying portable metabolomic technologies in selected healthcare facilities and assessing their ability to generate reliable data for AI-based disease prediction. Evaluation parameters should include diagnostic accuracy, sensitivity, specificity, cost-effectiveness, computational efficiency, and usability among healthcare professionals. Multi-site studies across different populations will also be required to evaluate model generalizability and reduce potential algorithmic bias.

Portable Technologies for Metabolomic Data Collection

Technology	Function	Possible Application
Portable mass spectrometry	Detects and identifies metabolites based on molecular mass	Disease biomarker detection and metabolic profiling
Lab-on-chip devices	Miniaturized biochemical analysis using microfluidics	Point-of-care metabolite testing
Paper-based biosensors	Low-cost chemical detection platforms	Rapid screening in rural healthcare settings
Portable Raman spectroscopy	Identifies molecular signatures using light-based analysis	Non-invasive metabolic analysis
Wearable biosensors	Continuous monitoring of biochemical markers	Real-time monitoring of metabolic changes
Smartphone-based diagnostic platforms	Connect sensors with AI analysis	Remote healthcare monitoring

Table 1: Examples of Portable Technologies Applicable to AI-Integrated Metabolomics

These technologies provide potential pathways for decentralized metabolomic data collection by reducing dependence on centralized laboratories. However, further evaluation is required to determine their affordability, analytical accuracy, durability, and suitability for low-resource healthcare environments.

Data Harmonization and Quality Management

Data fragmentation and inconsistent formats represent major barriers to AI-based healthcare systems in resource-constrained environments. To address these challenges, future implementations should adopt standardized protocols for sample collection, metabolite identification, and data reporting. Data preprocessing pipelines should incorporate normalization, quality control, missing-data management, and batch-effect correction. Furthermore, interoperability standards and collaborative data-sharing initiatives should be encouraged to improve dataset consistency. Emerging approaches such as federated learning may also enable institutions to improve AI models collaboratively while maintaining patient data privacy.

Ethical Oversight and Community Engagement

Ethical governance should be integrated throughout the development and deployment of AI-integrated metabolomics systems. Continuous oversight mechanisms involving healthcare professionals, researchers, policymakers, ethicists, and community representatives should be established to monitor data privacy, algorithmic fairness, transparency, and accountability. Community engagement should include participation in system design, pilot testing, and evaluation to ensure that technological solutions align with local healthcare priorities and cultural expectations.

Research Roadmap

Stage	Activity	Goal
Stage 1	Pilot implementation	Test feasibility
Stage 2	Technology assessment	Identify suitable portable tools
Stage 3	AI model validation	Evaluate prediction accuracy
Stage 4	Stakeholder engagement	Ensure ethical and sustainable adoption
Stage 5	Scaling	Expand to wider healthcare systems

Table 2: Stages of AI-Based Healthcare Implementation Framework

CONCLUSION

This study has presented a conceptual framework for integrating metabolomics and artificial intelligence (AI) to support predictive healthcare systems in resource-constrained environments. In the context of the growing global burden of non-communicable diseases, particularly in low- and middle-income regions, the need for early detection and proactive intervention has become increasingly critical. The proposed framework addresses this challenge by combining biologically informative metabolite data with advanced computational techniques to enable data-driven health prediction and decision-making.

A key contribution of this research lies in its interdisciplinary approach, linking metabolomic profiling with machine learning–based analytics within a scalable system architecture. By structuring the framework into distinct layers—ranging from data acquisition to clinical decision support—the study provides a clear pathway for transforming complex biological data into actionable healthcare insights. This approach supports early identification of disease risks, enhances diagnostic efficiency, and enables more targeted and personalized intervention strategies.

The framework also emphasizes adaptability to low-resource settings through the integration of portable diagnostic tools, cloud-enabled processing, and decentralized healthcare delivery models. These features are particularly relevant for expanding access to predictive healthcare services in underserved communities, where traditional diagnostic infrastructure may be limited. By enabling more efficient use of available resources, the model contributes to improving overall health system performance.

However, several challenges must be addressed to realize the full potential of AI-integrated metabolomics in practice. Variability in metabolomic data, infrastructure limitations, and the need for high-quality datasets present ongoing technical constraints. In addition, ethical considerations—including data privacy, transparency, and algorithmic fairness—require careful attention to ensure responsible implementation. Addressing these challenges will require coordinated efforts across scientific, technological, and policy domains.

Future research should focus on empirical validation of the proposed framework through pilot studies and real-world applications. There is also a need to explore the development of cost-effective metabolomic technologies and to improve data infrastructure in resource-limited settings. Further work on explainable AI models and bias mitigation strategies will be essential to enhance trust and ensure equitable outcomes across diverse populations.

In conclusion, the integration of metabolomics and artificial intelligence represents a promising pathway toward predictive and precision public health. By aligning technological innovation with the realities of resource-constrained environments, this study provides a foundation for advancing accessible, data-driven healthcare systems capable of addressing current and emerging global health challenges.

REFERENCES

1. World Health Organization. Legal environment assessment for the prevention of non-communicable diseases: an operational guide. World Health Organization; 2023.
2. Wishart DS. Applications of metabolomics in drug discovery and development. Drugs in R & D. 2008 Sep;9(5):307-22.
3. Patti GJ, Yanes O, Siuzdak G. Metabolomics: the apogee of the omics trilogy. Nature reviews Molecular cell biology. 2012;13(4): 263-9.
4. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-level classification of skin cancer with deep neural networks. nature. 2017 ;542(7639):115-8..
5. Topol E. Deep medicine: how artificial intelligence can make healthcare human again. Hachette UK; 2019.
6. Floridi L, Cowls J, Beltrametti M, Chatila R, Chazerand P, Dignum V, et al. AI4People—An ethical framework for a good AI society: Opportunities, risks, principles, and recommendations. Minds and machines. 2018;28(4):689-707.
7. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29(11): 1181-9.
8. Bollard ME, Stanley EG, Lindon JC, Nicholson JK, Holmes E. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR in Biomedicine: An

International Journal Devoted to the Development and Application of Magnetic Resonance In vivo. 2005;18(3):143-62.

9. Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nature reviews Drug discovery. 2016;15(7):473-84.
10. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. TRENDS in Biotechnology. 2004;22(5):245-52.
11. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nature reviews Molecular cell biology. 2016;17(7):451-9.
12. Chen L, Zhang X & Liang Y (2021). Machine learning for metabolomics: A comprehensive review. Briefings in Bioinformatics, 22(2), 1–18.
13. Ajay K, Smith R & Brown . (2020). Metabolomics in precision medicine: Current applications and future directions. Journal of Biomedical Science, 27(45), 1–15.
14. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nature reviews genetics. 2011;12(1):56-68.
15. Caporale N, Elgendy M & Sayed A. (2022). Artificial intelligence in healthcare: Past, present and future. The Lancet Digital Health, 4(6), e371–e372.
16. Kaddurah-Daouk R, Krishnan K. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology. 2009;34(1):173-86.
17. Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nature Reviews Microbiology. 2005;3(5):431-8.
18. Zhou J, Yin Y. Strategies for large-scale targeted metabolomics quantification by liquid chromatography-mass spectrometry. Analyst. 2016;141(23):6362-73.